We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Funding Shortfalls, Controversies Slow Critical Path Initiative
The FDA’s much-touted Critical Path Initiative, which is supposed to speed the introduction of new products to market, is being held back by limited agency funding, as well as several ongoing controversies, according to agency and industry officials.